Retatrutide

What is retatrutide?

Retatrutide (development code LY3437943) is a synthetic peptide studied as a triple receptor agonist. It activates the GLP-1, GIP and glucagon receptors, which makes it the most mechanistically ambitious compound in the metabolic peptide class and the reason researchers buy retatrutide for comparative work against single and dual agonists.

Semaglutide targets one receptor. Tirzepatide targets two. Retatrutide adds glucagon, a pathway associated with energy expenditure rather than appetite alone. That third target is the entire scientific interest, and it is also why the compound arrived later and carries thinner published data than its predecessors.

Retatrutide research applications

Published work on retatrutide has concentrated on metabolic regulation, appetite signalling and body composition endpoints. Phase 2 results published in 2023 attracted significant attention across endocrinology and metabolic research, and phase 3 programmes remain ongoing.

Laboratories sourcing this compound typically use it for receptor binding and selectivity studies, comparative agonist work against tirzepatide and semaglutide, metabolic pathway characterisation, and energy expenditure research where the glucagon component is the variable of interest.

How retatrutide works

The three receptors do different jobs. GLP-1 signalling slows gastric emptying and reduces appetite drive. GIP is a second incretin that appears to amplify GLP-1 effects when co-targeted, having been dismissed for years as the less useful of the two. Glucagon, counterintuitively for anyone who remembers it as the blood sugar hormone, is associated with increased energy expenditure when engaged alongside the incretins rather than in isolation.

Retatrutide is a 39-amino-acid peptide engineered for extended half-life, which is what makes weekly-interval study designs feasible in the published trial literature.

Buy retatrutide: specifications

Retatrutide vs tirzepatide vs semaglutide

The full comparison is covered in our guide to peptides for weight loss for women.

Reconstitution and handling

Retatrutide ships lyophilized and requires reconstitution with bacteriostatic water before use in solution. Introduce the diluent slowly against the vial wall rather than directly onto the powder, and allow the material to dissolve without agitation. Peptides are sensitive to shear force, and vigorous shaking degrades them.

Healio stocks bacteriostatic water for this purpose. The full procedure is covered in our reconstitution guide.

Storage and stability

Lyophilized retatrutide is stable for extended periods at minus 20 degrees Celsius in the original sealed vial, protected from light. Once reconstituted, the solution requires refrigeration and has a considerably shorter usable window. Avoid repeated freeze and thaw cycles, which are one of the most common causes of degradation in laboratory handling.

Certificate of analysis for every batch

Every retatrutide batch is tested by an independent, unaffiliated US analytical laboratory before it reaches a bench. Purity is quantified by HPLC and identity is confirmed by mass spectrometry. Lots below 98% purity are not shipped.

Certificates are published openly at our research page where you can read them before ordering rather than requesting them afterwards. We do not grade our own work, which is the entire point of third-party testing.

Why researchers buy retatrutide from Healio

Independent third-party testing on every batch, with the certificate published before purchase. Minimum 98% purity by HPLC with identity confirmed by mass spectrometry. US shipping with cold-chain dispatch. A deliberately narrow catalog built around compounds with research relevance to women rather than a general listing of everything available.

For a wider view of how to assess any supplier, including this one, see our comparison of the best peptide companies.

Retatrutide FAQ

What is retatrutide used for in research?

Metabolic and appetite signalling research, receptor selectivity studies, and comparative work against single and dual agonists. It is supplied strictly as a laboratory research material and is not for human use.

How does retatrutide differ from tirzepatide?

Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide adds a third, glucagon, which is associated with energy expenditure. Tirzepatide has the more mature published trial record; retatrutide has the broader mechanism and the newer data.

Is retatrutide FDA approved?

No. Retatrutide is an investigational compound in ongoing clinical development. It is supplied here for laboratory research only and has not been evaluated by the FDA for any use.

What purity is Healio retatrutide?

Minimum 98%, quantified by HPLC, with identity confirmed by mass spectrometry at an independent laboratory. The certificate for each batch is published before purchase.